BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | Oct 19, 2017
Finance

Broad umbrella

In its $50 million tie-up with the Broad Institute of MIT and Harvard , Deerfield Management is looking to forge a new mold of partnership with an academic organization that allows it to efficiently survey early...
BioCentury | Dec 16, 2016
Finance

Extending private runways

While the private biotech sector is seeing a serious influx of new venture capital, investors say not to expect a corresponding increase in the amount of new company formations. According to BioCentury’s BCIQ database, since...
BioCentury | Mar 14, 2016
Finance

Abingworth's early action

Abingworth's venture deal flow in the past 12 months reveals a clear preference for getting in early on companies that are generating pipelines of first- or best-in-class products. The latest biotech to match the profile...
BioCentury | Jul 25, 2011
Company News

Amira, Bristol-Myers deal

Bristol-Myers will acquire Amira for $325 million in cash, plus up to $150 million in milestones. Bristol-Myers will gain Amira's AM152 , an oral lysophosphatidic acid receptor 1 ( LPA1 ) antagonist that has completed Phase I testing...
BioCentury | May 8, 1995
Analyst Picks & Changes

Analyst picks & changes

Centocor Inc. (CNTO) Cowen & Co. analyst Joyce Lonergan maintained a "neutral" rating and advised investors to wait to invest until the third quarter, when more information on ReoPro sales will be available. Interim data,...
Items per page:
1 - 6 of 6
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BioCentury | Oct 19, 2017
Finance

Broad umbrella

In its $50 million tie-up with the Broad Institute of MIT and Harvard , Deerfield Management is looking to forge a new mold of partnership with an academic organization that allows it to efficiently survey early...
BioCentury | Dec 16, 2016
Finance

Extending private runways

While the private biotech sector is seeing a serious influx of new venture capital, investors say not to expect a corresponding increase in the amount of new company formations. According to BioCentury’s BCIQ database, since...
BioCentury | Mar 14, 2016
Finance

Abingworth's early action

Abingworth's venture deal flow in the past 12 months reveals a clear preference for getting in early on companies that are generating pipelines of first- or best-in-class products. The latest biotech to match the profile...
BioCentury | Jul 25, 2011
Company News

Amira, Bristol-Myers deal

Bristol-Myers will acquire Amira for $325 million in cash, plus up to $150 million in milestones. Bristol-Myers will gain Amira's AM152 , an oral lysophosphatidic acid receptor 1 ( LPA1 ) antagonist that has completed Phase I testing...
BioCentury | May 8, 1995
Analyst Picks & Changes

Analyst picks & changes

Centocor Inc. (CNTO) Cowen & Co. analyst Joyce Lonergan maintained a "neutral" rating and advised investors to wait to invest until the third quarter, when more information on ReoPro sales will be available. Interim data,...
Items per page:
1 - 6 of 6